bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives. The decision was made after a third and final denial by the Food & Drug Administration (FDA) of bluebird’s appeal for a priority review voucher, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!